While harmonising EU drug policies is unnecessary, it is important that states can learn from drug policy successes and failures in other countries.

Are drug policies in different European Union member states becoming more similar? Caroline Chatwin assesses the development of drug policies in European states and the potential for policies to become harmonised across the EU. She notes that while in some states there has been a trend toward more lenient policies focused on treatment; other countries, such as Sweden, have adopted a more repressive approach aimed at the complete removal of drug use from society. This lack of consensus is not necessarily problematic, however: the most important issue is ensuring that individual states do not become so locked into their own paradigms that they become unable to learn from the experiences of other countries

UNGASS 2016: Insights from Europe on the development of global cannabis policy and the need for reform of the global drug policy regime

This article is framed by the forthcoming United Nations General Assembly Special Session on drugs (UNGASS) debates on global drug policy. It explores European drug policy experiences to draw out important lessons and insights that could be applied to wider global drug policy regimes. European experiences with (i) diverse cannabis policies and (ii) longstanding attempts to harmonise or coordinate diverse national drug policies in general are examined and the results are extrapolated to global drug policy debates. The diversity of drug policy seen within EU borders should be viewed (i) as a strength, (ii) flexibility under the international conventions is possible, but has limitations, (iii) changes to the global drug policy regime should seek to increase flexibility, and (iv) the importance of international institutions in providing a framework and an evaluatory role should not be under emphasised. Collectively, the evidence suggests the need for the loosening of controls restricting the development of diverse drug policy innovations, and the development of international drug policy frameworks and international standards of drug-related data collection

The European Union in Panglossian Stagnation

This chapter provides a critical exploration of the European Union’s impact on the UNGASS 2016 proceedings and Outcome document. It demonstrates that the ability to produce a European ‘common position’ ahead of the UNGASS debates represents a significant step forward in the ability to ‘speak with one voice’ in the global illicit drug policy arena, and has played an important role in ensuring key issues such as human rights and public health remain on the agenda. In highlights, however, a European failure to engage with issues such as the continuing suitability of the international drug conventions to preside over the current climate of drug policy innovation and experimentation, and the unintended consequences of a ‘war on drugs’ approach. Ultimately, therefore, it argues that these failures will hamper the development of a more progressive and effective global drug policy

Gender Representations in Online Modafinil Markets

This chapter examines representations of gender in online modafinil markets. While gender has often been absent from scholarship on online drug markets, our analysis demonstrates the ubiquity of gender in representations of modafinil users and sellers. The analysis draws on visual images, blogs, and marketing emails relating to three websites selling modafinil, discussed pseudonymously. We describe the range of ways that notions of gender are represented in advertising. Although women represent around 40% of that buying modafinil online, websites and communications tended not to feature women. Although sexist stereotypes of women were rarely present (in contrast to direct-to-consumer pharmaceutical advertising), the ways that modafinil was imagined tended to focus narrowly on corporate spheres of work and productivity. We contrast this narrow imaginary with female journalists’ own accounts of using modafinil to manage illness and enhance creativity. Thus, we conclude that the ways that modafinil has been imagined reflects working assumptions as to who is considered the ‘normal’ participant in online modafinil markets

Assessing the ‘added value’ of European policy on new psychoactive substances

New Psychoactive Substances (NPS) are reported to be on the rise throughout Europe, and are often presented as the latest challenge facing drug-policy makers. At the European level, legislation on NPS has existed since 1998. Several evaluations, however, have suggested that this legislation is not effective and the European Commission has submitted a new proposal on NPS seeking to extend its powers in this area. This article critically evaluates the new proposal against its predecessor’s three main criticisms: (i) being unable to tackle the large number of NPS because of lengthy European legislative approaches, (ii) being reactive rather than proactive, and (iii) lacking options for regulatory and control measures. In determining whether or not European interventions can bring added value to what is being done at the national level, it finds that, while the new proposal is more efficient, it is not necessarily more effective, and that there is a disappointing focus on legal frameworks at the expense of research and harm reduction

Gendering Research on Online Illegal Drug Markets

This paper reviews and critiques research on online illegal drug markets, arguing that existing conceptualisations and methodological approaches have resulted in a very limited discussion of women and questions of gender. The first part lays out the stereotypes and unarticulated assumptions that enable questions about women and gender to be side-lined, as follows: i) that online anonymity rules out knowing about gender in online drug markets; (ii) that online drug markets are male-dominated spaces; and iii) that women are limited to minor or peripheral roles in those markets. Our aim is to make apparent, and challenge the marginalisation of enquiry about women and gender in existing scholarship about online illegal drug markets. In the second part, we draw on scholarship on women and gender in the drug trade more generally to consider what studying online illegal drug markets might add to our understanding of both women’s participation in these markets and the way in which gender is more widely performed. We consider whether online markets may facilitate women’s participation (due to anonymity, for example), or whether online drug markets replicate gendered stratifications characteristic of offline markets. We also explore the potential significance of women’s participation in online illegal drug markets for harm reduction services. In conclusion, we suggest that future research should challenge the assumption that we can understand online markets without thinking about gender and outline the steps towards building a gendered perspective in this area

Gender Representations in Online Modafinil Markets

This chapter examines representations of gender in online modafinil mar- kets. While gender has often been absent from scholarship on online drug markets, our analysis demonstrates the ubiquity of gender in representa- tions of modafinil users and sellers. The analysis draws on visual images, blogs, and marketing emails relating to three websites selling modafinil, discussed pseudonymously. We describe the range of ways that notions of gender are represented in advertising. Although women represent around 40% of that buying modafinil online, websites and communications tended not to feature women. Although sexist stereotypes of women were rarely present (in contrast to direct-to-consumer pharmaceutical advertising), the ways that modafinil was imagined tended to focus narrowly on corpo- rate spheres of work and productivity. We contrast this narrow imaginary with female journalists’ own accounts of using modafinil to manage illness and enhance creativity. Thus, we conclude that the ways that modafinil has been imagined reflects working assumptions as to who is considered the ‘normal’ participant in online modafinil markets

Liminal spaces, seasonal faces: Challenging drug market assumptions via an exploration of naturally occurring magic mushroom markets in rural Kent

This article presents an exploration of naturally occurring Class-A magic mushroom markets in the UK. It aims to challenge some of the mainstream narratives about drug markets and to identify features of this specific market, which will extend our understanding of how illegal drug markets operate and are structured more generally. The research presented comprises a three year ethnography of sites of magic mushroom production in rural Kent. Observations were conducted at 5 research sites over three consecutive magic mushroom seasons and interviews were conducted with 10 (8 male; 2 female) key informants. It finds that naturally occurring magic mushroom sites are reluctant and liminal sites of drug production, distinct from other Class-A drug production sites due to their: open and accessible nature; lack of invested ownership or evidence of purposeful cultivation; and lack of law enforcement disruption efforts, violence or organised crime involvement. Seasonal magic mushroom picker participants were found to be a sociable group, often acting in a cooperative nature, and without evidence of territoriality or violent dispute resolution. These findings have wider application in challenging the dominant narrative that the most harmful (Class-A) drug markets are homogenous in their violent, profit driven, hierarchical nature, and most Class-A drug producers/suppliers are morally corrupt, financially motivated and organised. A greater understanding of the variety of Class-A drug markets in operation can challenge archetypes and discrimination in understanding drug market involvement, will allow the development of more nuanced policing and policy strategies, and contributes to the presentation of a fluidity of drug market structure that permeates beyond bottom level street markets or social supply

The role of foot pressure measurement in the prediction and prevention of diabetic foot ulceration – a comprehensive review

Diabetic foot ulcers (DFU) are a costly public health concern. The predominant risk factor, peripheral neuropathy, results in loss of protective sensation and is associated with abnormally high plantar pressures. DFU prevention strategies, including orthotics and footwear, strive to reduce these high plantar pressures. Nevertheless, several constraints should be acknowledged regarding the research supporting the link between plantar pressure and DFUs. The majority of studies assess vertical, rather than shear, barefoot plantar pressure in laboratory-based environments, rather than during daily activity. Few studies investigated previous DFU location-specific pressure. Previous studies focus predominantly on walking, although studies monitoring activity suggest that more time is spent on other weight-bearing activities, where a lower ‘peak’ pressure might be applied on the foot over a longer duration. Although further research is needed, this may indicate that an expression of cumulative pressure applied over time, such as pressure-time integral, could be a more relevant parameter than peak pressure. A few studies have indicated that providing pressure feedback to the patient might reduce plantar pressures, with an emerging potential use of smart technology. However, further research is required to determine the efficacy of this approach. Constraints of previous plantar pressure research may explain its low prediction ability for DFU as part of prospective studies. Further vertical and shear pressure analyses, across all weight-bearing activities and referring to location-specific pressures are required to improve our understanding of pressures resulting in DFUs and to help improve effectiveness of interventions, such as therapeutic footwear and pressure-feedback